Expert Analysis

Breast Cancer

Source: CCO Independent Conference Coverage of the 2007 American Society of Clinical Oncology Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Breast Cancer

Faculty:
William J. Gradishar, MD, FACP Clifford A. Hudis, MD Christy Russell, MD
George W. Sledge, Jr., MD

CME CREDIT INFORMATION

Release Date: 08/09/07

Expiration Date: 08/08/08

Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.5 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize data from recent studies regarding treatment of patients with ductal carcinoma in situ
Discuss the use of chemotherapy combinations and/or novel agents in the treatment of advanced or metastatic breast cancer
Review the efficacy of several novel targeted therapies and cytotoxic therapies currently under evaluation for the treatment of metastatic breast cancer
Describe different challenges in the use of HER2 testing for patients with breast cancer
Articulate recent data concerning the use of gene expression profiling to guide treatment

Topics covered include:

Trials Evaluating Ductal Carcinoma in Situ and Survival Outcomes
Comparisons of Taxane Type and Schedules in Adjuvant Therapy for Breast Cancer
Use of Axitinib and Docetaxel Combination in Metastatic Breast Cancer
Trastuzumab Combinations in Metastatic Breast Cancer
Use of Targeted Therapy With Lapatinib in Metastatic Breast Cancer
Everolimus as Single-Agent Treatment in Metastatic Breast Cancer
Use of Conventional Chemotherapy in Metastatic Breast Cancer
Mathematical Modeling to Predict Optimal Chemotherapy Dosing for Capecitabine
HER2 Testing Issues in Metastatic Breast Cancer
Indicators of Response to Chemotherapy in Breast Cancer

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.